The median melanoma-specific survival was not reached in patients who received nivolumab plus ipilimumab, 49.4 months in those who received nivolumab alone, and 21.9 months in those who received ...

Ahmad Tarhini, MD, PhD: This was a first-line patient population with untreated metastatic melanoma who were randomly assigned 1:1 to a fixed-dose combination of nivolumab at 480 mg and relatlimab at ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash.

Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year overall and melanoma-specific survival (MSS) compared with ipilimumab alone in ...

CM24+nivolumab+Nal-IRI/5FU/LV treatment of PDAC ... add supporting evidence for NETs as a new mechanism of action (MoA) and potential biomarker for CM24-based therapy,” said Dr. Hadas Reuveni ...

High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC ...